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Received August 13, 2015; accepted October 11, 2015AbstractBackground: Theta burst stimulation is a type of pattern-specific repetitive transcranial magnetic stimulation that requires less stimulation time
and lower intensity to induce long-lasting effects comparable to those of other repetitive transcranial magnetic stimulation protocols. This pilot
study investigated whether continuous theta burst stimulation (cTBS) on the primary motor cortex reduced headache frequency in patients with
migraine.
Methods: Nine patients with migraine were recruited into our study. All patients received 20 cTBS sessions (bursts of 3 50-Hz TMS pulses at
200-ms intervals for 40 seconds), administered every weekday for 4 consecutive weeks. All patients kept headache diaries for 4 weeks before
stimulation (baseline; T1), during stimulation (T2), and 4 weeks after stimulation (T3). The primary outcome measures were the changes of total
headache and migraine days from baseline (Wilcoxon signed-rank test; T2 and T3 vs. T1).
Results: The number of total headache days was reduced at T2 and T3 compared with T1 [9.4 ± 6.2 days ( p ¼ 0.024) and 8.7 ± 10.1 days
( p ¼ 0.012) vs. 13.4 ± 10.1 days]. The number of migraine days was also reduced at T2 and T3 compared with T1 [2.9 ± 2.7 days ( p ¼ 0.021)
and 1.0 ± 1.6 days ( p ¼ 0.008) vs. 8.6 ± 8.7 days].
Conclusion: Our results indicate that cTBS on the primary motor cortex might reduce the number of total headache and migraine days in patients
with migraine. However, large-scale randomized controlled trials are necessary to further validate the findings.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Migraine is one of the most common neurological disor-
ders, and it causes severe disability. The World Health Orga-
nization ranked migraine among the 20 most disabling
diseases,1 and classified severe migraine as having the highest
level of functional disability, compatible with major depres-
sion disorder, quadriplegia, and terminal malignancy, in its
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Taiwan, the estimated prevalence of migraine is 9.1% (~150
million people; 14.4% in women and 4.5% in men).5 This dis-
order results in an estimated 3.7 million missed workdays,
incurring an annual cost of approximately NT$4.6 billion.6
Migraine thus imposes a heavy burden not only on individuals,
but also on families and society. As prophylactic medications for
migraine have adverse effects and cannot completely prevent
migraine attacks, nonmedicinal alternatives are needed.
In recent years, hyper-excitability of the central nervous
system (CNS) has been demonstrated in patients with
migraine.7 The modulation of CNS excitability (i.e., neuro-
modulation) provides an opportunity for nonpharmacological
treatment of these patients. Since its introduction in 1985,
repetitive transcranial magnetic stimulation (rTMS) has been
shown to effectively modulate CNS excitability through the
modification of synaptic plasticity.8 Low-frequency rTMS (
1 Hz) can reduce cortical excitability, whereas high fre-
quencies ( 5 Hz) can correspondingly increase it. Addi-
tionally, rTMS has been previously used for several
therapeutic purposes,9 including the treatment of chronic
pain10,11 and migraine.12,13
Theta burst stimulation (TBS) is a pattern-specific type of
rTMS. Compared with conventional rTMS protocols, TBS
requires less stimulation time and lower intensity to induce
comparably long-lasting effects in the human cerebral cor-
tex.14 The use of conventional rTMS paradigms to relieve
provoked acute or experimental pain has been reported.15 The
continuous TBS (cTBS) had an inhibitory effect on the
excitability of the cerebral cortex.14 However, the use of cTBS
as an antinociceptive approach has not been well studied. In
this study, we explored whether the application of cTBS to the
primary motor cortex (M1) in patients with migraine reduced
migraine frequency.
2. Methods2.1. PatientsPatients with migraine were recruited for this pilot study
from the Headache Clinic of Taipei Veterans General Hospital,
Taipei, Taiwan. No participant had prior rTMS experience, a
cardiac or cerebral pacemaker, metal in the cranium, epilepsy,
pregnancy, and any systemic or neurological disease. The
diagnosis of migraine was based on the criteria of the Inter-
national Classification of Headache Disorders, 2nd edition.16
All participants completed a detailed headache intake form
at the time of recruitment.
Prior to entering the study, all participants had to provide
signed informed consent. The Institutional Review Board of
Taipei Veterans General Hospital approved the study protocol
(VGHIRB No.: 95-02-01).2.2. rTMSFig. 1. Outcome evaluation. cTBS ¼ continuous theta burst stimulation;
T2 ¼ during stimulation; T3 ¼ 4 weeks after stimulation.Each patient sat in a comfortable chair and was asked to
relax. A recording electrode was placed on the left abductorpollicis brevis (APB) muscle, and a reference electrode was
placed on the metacarpalephalangeal joint. After that, motor-
evoked potential signals were displayed on a conventional
electromyographic machine (Neuropack M1; Nihon Kohden,
Tokyo, Japan). We first determined the “hot spot” (M1APB) for
activation of the left APB muscle, where stimuli-evoked motor
potentials had the maximal peak-to-peak amplitude. The coil
was moved in 5-mm increments to determine the optimal scalp
position. We then determined the resting motor threshold
(RMT) at the hot spot, which was defined as the minimum
stimulation intensity required to evoke a motor-evoked po-
tential > 50 mV in at least five of 10 trials.2.3. Stimulation protocolAfter the stimulation site (M1APB) and intensity (RMT)
were determined, rTMS (cTBS) was delivered to the M1APB
through a figure-eight coil connected to a Magstim Rapid
magnetic stimulator (Magstim Co., Whitland, Dyfed, UK).
cTBS consisted of bursts of three 50-Hz TMS pulses,
repeated at 200-ms intervals for 40 seconds. The intensity
was set at 80% of each patient's RMT. The coil was placed
tangentially to the scalp, approximately 45 from the midline,
and the handle of the coil was angled 45 posterolaterally.
Treatment consisted of 20 rTMS (cTBS) sessions, delivered
every weekday for 4 consecutive weeks. All patients received
cTBS.2.4. Outcome evaluationAll participants kept headache diaries for 4 weeks before
stimulation (baseline; T1), during stimulation (T2), and
4 weeks after stimulation (T3); they submitted their diaries at
the conclusion of each time period. The primary outcome
measures were the changes of total headache and migraine
headache days from baseline, i.e., T2 versus T1 and T3 versus
T1. The secondary outcome measures were the frequency of
migraine abortive medicine use, Beck Depression Inventory
(BDI), and Hospital Anxiety and Depression Scale (HADS)
total (T) scores in each time period, and changes from baseline
(Fig. 1).2.5. Safety and tolerability measuresWe recorded spontaneously reported treatment-emergent
adverse events during each visit. Patients' vital signs were
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tions were conducted during each visit.2.6. Statistical analysisAll analyses were performed with SPSS version 21.0
software (IBM, Armonk, NY, USA). The Wilcoxon signed-
rank test was used for analyzing the changes of primary and
secondary outcomes at T2 and T3 compared with T1. Spear-
man's rank correlation coefficients (rs) were used to determine
the association between the change of total headache or
migraine frequencies and BDI scores. Nonparametric tests
were used due to the small number of observations and po-
tential violation of the normality assumption. Statistical sig-
nificance was defined as p < 0.05, and all tests were two-
tailed.
3. Results
Nine patients (1 man, 8 women) with a mean age of
35.8 ± 10.5 (range, 32e51) years participated in the study.
The mean duration of headache history was 12.8 ± 6.5 (range,
3e17) years. The patients used analgesics on an average of
4.3 ± 3.4 (range, 2e10) days per month. Three (33.3%) of the
patients had chronic migraine and had been taking prophy-
lactic medication (metoprolol, propanolol, or topiramate) for
at least 3 months (Table 1).3.1. Primary outcome measurescTBS significantly reduced the mean number of total
headache days per month, from 13.4 ± 10.1 days at T1 to
9.4 ± 6.2 days at T2 ( p ¼ 0.024) and 8.7 ± 10.1 days at T3
( p ¼ 0.012). The mean number of migraine days per month
was also reduced significantly, from 8.6 ± 8.7 days at T1 toTable 1
Baseline demographic characteristics and headache profiles of participants
(n ¼ 9).
Parameter Mean ± SD (range) or n (%)
Age (y) 35.8 ± 10.5 (24e51)
Sex
Male 1 (11.1)
Female 8 (88.9)
BMI (kg/m2) 21.9 ± 2.7 (19.1e25.7)
Duration of headache history (y) 12.8 ± 6.5 (3e17)
Migraine diagnosis
Episodic migraine 6 (66.7)
Chronic migraine 3 (33.3)
Total headache frequency (d/mo)a 7.78 ± 6.2 (3e20)
Analgesic use (d/mo)a 4.3 ± 3.4 (2e10)
BDI score 9.2 ± 8.4 (3e30)
HADS-T score 34.7 ± 2.7 (31e38)
Total headache (d) 13.4 ± 10.1 (3e29)
Migraine (d) 8.6 ± 8.7 (1e28)
BDI ¼ Beck Depression Inventory; BMI ¼ body mass index; HADS-
T ¼ Hospital Anxiety and Depression Scale total scores; SD ¼ standard
deviation.
a Average of past 3 months.2.9 ± 2.7 days at T2 ( p ¼ 0.021) and 1.0 ± 1.6 days at T3
( p ¼ 0.008; Fig. 2).3.2. Secondary outcome measuresThe frequency of abortive medication use per month was
reduced significantly compared with baseline (3.8 ± 3.0 days)
at T3 (2.4 ± 3.3 days, p ¼ 0.042), but not at T2
(2.8 ± 2.7 days, p ¼ 0.084). The mean BDI score was also
significantly lower than baseline (9.2 ± 8.4) at T3 (4.8 ± 6.0,
p ¼ 0.012), but not at T2 (7.2 ± 11.3, p ¼ 0.16). By contrast,
no change in mean HADS-T score from baseline (34.7 ± 2.7)
was observed (T2: 36.0 ± 1.5, p ¼ 0.776; T3: 34.6 ± 4.3,
p ¼ 0.888). According to the Spearman's rank correlation
analyses, the changes of total headache or migraine days were
not associated with the change of the BDI scores, where total
headache days T2: rs ¼ 0.021, p ¼ 0.957; T3: rs ¼ 0,017,
p ¼ 0.965; migraine days: T2: rs ¼ 0.193, p ¼ 0.618; T3:
rs ¼ 0.266, p ¼ 0.489.3.3. Adverse eventsNo significant adverse events were reported during the
experimental period.
4. Discussion
In this study, we demonstrated that the application of cTBS
over the M1 area effectively reduced headache frequency. The
4-week cTBS treatment significantly reduced the number of
total headache and migraine days, and this effect persisted
4 weeks after treatment. The effect on sizes of the reduction in
the mean frequency of all headaches and migraines were
4.7 days and 7.6 days per month, respectively, exceeding those
reported previously for pharmacological treatment (average
0.5e2 days per month).17e20 Our results are similar to those of
a previous study, in which acupuncture reduced the mean
number of headache days per month from 20.2 ± 1.5 days to
9.8 ± 2.8 days. cTBS and acupuncture thus appear to have
more substantial effects than prophylactic migraine medica-
tion.21 However, these effects were not associated with
improvement of depression or anxiety in the present study, as
BDI and HADS-T scores were not correlated with improve-
ment in total headache or migraine frequency.
However, there have been some studies applying rTMS to
modulate the cortical excitability in patients with migraine,
which resulted in clinical improvement.
Brighina et al22 in 2004 first demonstrated the positive effects
of high-frequency rTMS application over the left dorsolateral
prefrontal cortex (DLPFC) in patients with chronic migraine, in
terms of decreased frequencies of migraine attack and analgesic
use, as well as reduced headache impact. However, no such
effect was observed in a subsequent large-scale randomized
double-blind study, in which a similar high-frequency rTMS
protocol was utilized for 18 patients with chronic migraine.23
This discrepancy in findings may result from differences in
patient selection and stimulation protocols. However, one
Fig. 2. Total headache and migraine days at baseline, during stimulation, and 4 weeks after stimulation. T1 ¼ baseline; T2 ¼ during stimulation; T3 ¼ 4 weeks
after stimulation.
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may modify the attentive and emotional aspects of pain, rather
than the perception of pain itself. This modality is also likely to
be beneficial in reducing the symptoms of depression.24 Thus,
the discrepancy between these two studies may derive from
baseline differences in the participants' psychiatric comorbid-
ities. The effect of high-frequency rTMS over the DLPFC on
migraine prophylaxis may therefore require further evaluation.
The M1 is another target of choice. Histological25 and
neurophysiological26 studies have clearly demonstrated the
intimate connection between M1 and the primary somato-
sensory cortex (S1). Furthermore, it has also been demon-
strated that M1 stimulation exerts its modulation effect on S1
more pronouncedly than direct S1 stimulation27 or stimulation
on the other cortices,28 providing the basis for M1 modulation
in reducing pain perception.9e11 As S1 is also responsible for
pain perception in migraine headache,29 modulation of S1
excitability through M1eS1 connection is a reasonable
approach.
Misra et al12 demonstrated that high-frequency rTMS over
the M1 reduced headache frequency and severity, analgesic
usage, and functional impairment in patients with migraine. It
may conflict with the concept that one should reduce cortical
excitability by low-frequency rTMS through its inhibitory
effect in treating patients with migraine. However, it was
recently proposed that repeated pain perception may alter the
responses to rTMS in patients with migraine, throughout the
metaplasticity effect.30 The effect of high-frequency rTMS in
patient with migraine are therefore more likely inhibitory than
excitatory as observed in normal individuals. As cTBS also
exerts its modulation through an inhibitory effect, our results
are consistent with those of Misra et al's12 study. Our results
suggest that cTBS over the M1 has a migraine prophylactic
effect similar to that of high-frequency rTMS over the sameregion. As cTBS can be delivered within 1 minute, which is
only one-fifteenth to one-tenth the duration of high-frequency
rTMS treatment, it may provide better patient compliance with
noninvasive brain stimulation in a clinical setting.
The exact mechanisms by which cTBS over the M1 area
ameliorates headache frequency remains unknown. The effect
of rTMS (including TBS) is known to be due to long-term
potentiation/depression-like modification of synaptic trans-
mission,31 and later to a genetic modification effect (gene
transcription and protein synthesis) in perisynaptic cells.32,33
The modulation of cortical hyper-excitability may have ther-
apeutic effects in patients with migraine.
This study had several limitations. It was exploratory and
involved a small number of patients and a single active
treatment component. However, the significant effects
observed despite these limitations suggest that the study re-
sults were not likely false positive. Nevertheless, further large-
scale studies with a sham control group are warranted.
In conclusion, the results of this study suggest the potential
of rTMS using a cTBS paradigm over the M1 as an alternative
migraine treatment strategy. This treatment was well tolerated
and may be effective as a migraine prophylaxis. However,
large-scale randomized controlled trials are required to vali-
date our findings.
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